A rational approach for a phase I clinical study design to evaluate CNTO 95, a novel, fully human anti-avmonoclonal antibody (MAb), in patients with solid tumors ...
Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results This is an ASCO Meeting Abstract from the 2009 ASCO Annual Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback